ENDPOINTS

Wave strengthens case for accelerated approval, with more positive Duchenne data

Wave Life Sciences shared updated results from a Phase 2 trial of its exon-skipping oligonucleotide candidate in Duchenne muscular dystrophy, bolstering its plans to file for accelerated approval next year. The biotech

Mar 26, 2025 - 16:21
 0
Wave strengthens case for accelerated approval, with more positive Duchenne data
Wave Life Sciences shared updated results from a Phase 2 trial of its exon-skipping oligonucleotide candidate in Duchenne muscular dystrophy, bolstering its plans to file for accelerated approval next year. The biotech
Read More

Tags:

Previous Article

What time is the partial solar eclipse on March 29?

Next Article

Never-before-seen chain of volcanoes discovered hiding near the Cook Islands

Related Posts

Novo Nordisk’s rare disease ‘company within a company’ has an open goal in sickle cell

Novo Nordisk’s rare disease ‘company within a company’ ...

Mar 6, 2025  0

Biohaven’s ion channel drug fails pivotal bipolar mania study

Biohaven’s ion channel drug fails pivotal bipolar mania...

Mar 3, 2025  0

OpenAI meets cancer care

OpenAI meets cancer care

Feb 27, 2025  0